Emerging precision diagnostics in advanced cutaneous squamous cell carcinoma

Glenn Geidel; Isabel Heidrich; Julian Kött; Stefan W Schneider; Klaus Pantel; Christoffer Gebhardt

doi:10.1038/s41698-022-00261-z

Emerging precision diagnostics in advanced cutaneous squamous cell carcinoma

Standard

Emerging precision diagnostics in advanced cutaneous squamous cell carcinoma. / Geidel, Glenn ; Heidrich, Isabel ; Kött, Julian ; Schneider, Stefan W ; Pantel, Klaus ; Gebhardt, Christoffer.

In: NPJ PRECIS ONCOL, Vol. 6, No. 1, 17, 23.03.2022.

Research output: SCORING: Contribution to journal › SCORING: Review article › Research

Harvard

Geidel, G , Heidrich, I , Kött, J , Schneider, SW , Pantel, K & Gebhardt, C 2022, 'Emerging precision diagnostics in advanced cutaneous squamous cell carcinoma', NPJ PRECIS ONCOL, vol. 6, no. 1, 17. https://doi.org/10.1038/s41698-022-00261-z

APA

Geidel, G., Heidrich, I., Kött, J., Schneider, S. W., Pantel, K., & Gebhardt, C. (2022). Emerging precision diagnostics in advanced cutaneous squamous cell carcinoma. NPJ PRECIS ONCOL, 6(1), [17]. https://doi.org/10.1038/s41698-022-00261-z

Vancouver

Geidel G , Heidrich I , Kött J , Schneider SW , Pantel K , Gebhardt C. Emerging precision diagnostics in advanced cutaneous squamous cell carcinoma. NPJ PRECIS ONCOL. 2022 Mar 23;6(1). 17. https://doi.org/10.1038/s41698-022-00261-z

Bibtex

@article{11c568d5a5da427face0a3deac8bb17e,

title = "Emerging precision diagnostics in advanced cutaneous squamous cell carcinoma",

abstract = "Advanced cutaneous squamous cell carcinoma (cSCC) encompasses unresectable and metastatic disease. Although immune checkpoint inhibition has been approved for this entity recently, a considerable proportion of cases is associated with significant morbidity and mortality. Clinical, histopathological, and radiological criteria are used for current diagnostics, classification, and therapeutic decision-making. The identification of complex molecular biomarkers to accurately stratify patients is a not yet accomplished requirement to further shift current diagnostics and care to a personalized precision medicine. This article highlights new insights into the mutational profile of cSCC, summarizes current diagnostic and therapeutic standards, and discusses emerging diagnostic approaches with emphasis on liquid biopsy and tumor tissue-based analyses.",

author = "Glenn Geidel and Isabel Heidrich and Julian K{\"o}tt and Schneider, {Stefan W} and Klaus Pantel and Christoffer Gebhardt",

note = "{\textcopyright} 2022. The Author(s).",

year = "2022",

month = mar,

day = "23",

doi = "10.1038/s41698-022-00261-z",

language = "English",

volume = "6",

journal = "NPJ PRECIS ONCOL",

issn = "2397-768X",

publisher = "Springer Nature",

number = "1",

}

RIS

TY - JOUR

T1 - Emerging precision diagnostics in advanced cutaneous squamous cell carcinoma

AU - Geidel, Glenn

AU - Heidrich, Isabel

AU - Kött, Julian

AU - Schneider, Stefan W

AU - Pantel, Klaus

AU - Gebhardt, Christoffer

PY - 2022/3/23

Y1 - 2022/3/23

N2 - Advanced cutaneous squamous cell carcinoma (cSCC) encompasses unresectable and metastatic disease. Although immune checkpoint inhibition has been approved for this entity recently, a considerable proportion of cases is associated with significant morbidity and mortality. Clinical, histopathological, and radiological criteria are used for current diagnostics, classification, and therapeutic decision-making. The identification of complex molecular biomarkers to accurately stratify patients is a not yet accomplished requirement to further shift current diagnostics and care to a personalized precision medicine. This article highlights new insights into the mutational profile of cSCC, summarizes current diagnostic and therapeutic standards, and discusses emerging diagnostic approaches with emphasis on liquid biopsy and tumor tissue-based analyses.

AB - Advanced cutaneous squamous cell carcinoma (cSCC) encompasses unresectable and metastatic disease. Although immune checkpoint inhibition has been approved for this entity recently, a considerable proportion of cases is associated with significant morbidity and mortality. Clinical, histopathological, and radiological criteria are used for current diagnostics, classification, and therapeutic decision-making. The identification of complex molecular biomarkers to accurately stratify patients is a not yet accomplished requirement to further shift current diagnostics and care to a personalized precision medicine. This article highlights new insights into the mutational profile of cSCC, summarizes current diagnostic and therapeutic standards, and discusses emerging diagnostic approaches with emphasis on liquid biopsy and tumor tissue-based analyses.

U2 - 10.1038/s41698-022-00261-z

DO - 10.1038/s41698-022-00261-z

M3 - SCORING: Review article

C2 - 35322182

VL - 6

JO - NPJ PRECIS ONCOL

JF - NPJ PRECIS ONCOL

SN - 2397-768X

IS - 1

M1 - 17

ER -